NO2015011I1 - Dasabuvir eller et salt derav, inkludert dasabuvir natrium monohydrat - Google Patents

Dasabuvir eller et salt derav, inkludert dasabuvir natrium monohydrat

Info

Publication number
NO2015011I1
NO2015011I1 NO2015011C NO2015011C NO2015011I1 NO 2015011 I1 NO2015011 I1 NO 2015011I1 NO 2015011 C NO2015011 C NO 2015011C NO 2015011 C NO2015011 C NO 2015011C NO 2015011 I1 NO2015011 I1 NO 2015011I1
Authority
NO
Norway
Prior art keywords
dasabuvir
salt
sodium monohydrate
crystalline forms
dihydropyrimidin
Prior art date
Application number
NO2015011C
Other languages
English (en)
Norwegian (no)
Other versions
NO2015011I2 (no
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of NO2015011I2 publication Critical patent/NO2015011I2/no
Publication of NO2015011I1 publication Critical patent/NO2015011I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO2015011C 2007-09-17 2015-04-22 Dasabuvir eller et salt derav, inkludert dasabuvir natrium monohydrat NO2015011I1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97288107P 2007-09-17 2007-09-17
US9679208P 2008-09-13 2008-09-13
PCT/US2008/076592 WO2009039134A1 (en) 2007-09-17 2008-09-17 Anti-infective pyrimidines and uses thereof

Publications (2)

Publication Number Publication Date
NO2015011I2 NO2015011I2 (no) 2015-04-22
NO2015011I1 true NO2015011I1 (no) 2015-05-04

Family

ID=40308557

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2015011C NO2015011I1 (no) 2007-09-17 2015-04-22 Dasabuvir eller et salt derav, inkludert dasabuvir natrium monohydrat

Country Status (22)

Country Link
US (3) US8188104B2 (xx)
EP (3) EP2639226B1 (xx)
JP (3) JP5734655B2 (xx)
CN (4) CN101842360B (xx)
AT (1) ATE519746T1 (xx)
CA (2) CA2849420C (xx)
CY (3) CY1115514T1 (xx)
DK (3) DK2203431T3 (xx)
ES (3) ES2592961T3 (xx)
HK (2) HK1148273A1 (xx)
HR (2) HRP20110809T1 (xx)
HU (1) HUS1500013I1 (xx)
LT (1) LTC2203431I2 (xx)
LU (1) LU92666I2 (xx)
MX (1) MX2010002902A (xx)
NL (1) NL300729I2 (xx)
NO (1) NO2015011I1 (xx)
PL (3) PL2203431T3 (xx)
PT (3) PT2203431E (xx)
RU (2) RU2014147354A (xx)
SI (2) SI2368882T1 (xx)
WO (1) WO2009039134A1 (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI437994B (zh) * 2007-09-17 2014-05-21 Abbvie Bahamas Ltd 抗感染劑及其用途
DK2203430T3 (da) 2007-09-17 2011-09-26 Abbott Lab N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
CN101842360B (zh) * 2007-09-17 2014-12-17 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
AU2009273327A1 (en) * 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CN102164909A (zh) 2008-09-26 2011-08-24 弗·哈夫曼-拉罗切有限公司 用于治疗hcv的吡啶或吡嗪衍生物
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
MX2011010047A (es) * 2009-03-25 2011-10-11 Abbott Lab Compuestos antivirales y usos de los mismos.
EP2421831A1 (en) 2009-04-25 2012-02-29 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
BRPI1011744A2 (pt) 2009-06-24 2016-03-22 Hoffmann La Roche composto antiviral heterocíclico.
CN102498100A (zh) 2009-09-21 2012-06-13 弗·哈夫曼-拉罗切有限公司 抗病毒杂环化合物
MX338041B (es) 2009-09-25 2016-03-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especificos de lisina y su uso.
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
CA2778206A1 (en) * 2009-11-21 2011-05-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
AU2010333338A1 (en) * 2009-12-14 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
WO2011073114A1 (en) * 2009-12-14 2011-06-23 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
ES2607081T3 (es) 2010-04-19 2017-03-29 Oryzon Genomics, S.A. Inhibidores de desmetilasa específica de lisina-1 y su uso
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US8895737B2 (en) * 2010-07-16 2014-11-25 Shashank Shekhar Process for preparing antiviral compounds
NZ704603A (en) 2010-07-16 2016-06-24 Abbvie Inc Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
LT2598482T (lt) 2010-07-29 2018-07-10 Oryzon Genomics, S.A. Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
BR112014009306B1 (pt) 2011-10-20 2021-07-20 Oryzon Genomics S.A. Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1
CA2849564C (en) 2011-10-20 2020-10-20 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) * 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
WO2014031791A1 (en) 2012-08-21 2014-02-27 Abbvie Inc. Process for preparing antiviral compounds
CN104853752B (zh) * 2012-10-18 2018-10-23 艾伯维公司 嘧啶二酮衍生物化合物的制剂
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015197028A1 (en) * 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2017160933A1 (en) * 2016-03-17 2017-09-21 Fmc Corporation Process for converting s-enantiomer to its racemic form
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017202207A1 (zh) * 2016-05-27 2017-11-30 深圳市塔吉瑞生物医药有限公司 一种取代的萘环化合物及药物组合物及其应用
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
AU627906B2 (en) * 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5084084A (en) * 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
ATE169915T1 (de) * 1990-02-15 1998-09-15 Takeda Chemical Industries Ltd Pyrimidindionderivate, deren herstellung und verwendung
NL9001075A (xx) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
PL207160B1 (pl) 1999-12-06 2010-11-30 Hoffmann La Roche Pochodne 4-pirymidynylo-N-acylo-L-fenyloalaniny, związki pośrednie, środek farmaceutyczny i ich zastosowanie
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
IL167954A (en) * 2000-02-04 2007-10-31 Sumitomo Chemical Co History of pyrimidine
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
BR0307712A (pt) * 2002-02-14 2005-05-24 Pharmasset Ltd Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
MXPA05005547A (es) * 2002-11-28 2005-07-26 Schering Ag Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 Ｃ형 간염 바이러스의 억제제
EP1651631A1 (en) * 2003-08-01 2006-05-03 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP2008506702A (ja) * 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
WO2007058392A1 (ja) * 2005-11-21 2007-05-24 Japan Tobacco Inc. ヘテロ環化合物およびその医薬用途
CN101842360B (zh) 2007-09-17 2014-12-17 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
DK2203430T3 (da) 2007-09-17 2011-09-26 Abbott Lab N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
TWI437994B (zh) * 2007-09-17 2014-05-21 Abbvie Bahamas Ltd 抗感染劑及其用途
AU2009273327A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds

Also Published As

Publication number Publication date
EP2368882B1 (en) 2014-08-13
EP2203431B1 (en) 2011-08-10
DK2639226T3 (en) 2016-12-19
PL2639226T3 (pl) 2017-02-28
MX2010002902A (es) 2010-06-02
CN104628655A (zh) 2015-05-20
DK2203431T3 (da) 2011-11-21
US20090186912A1 (en) 2009-07-23
US8501238B2 (en) 2013-08-06
CA2849420A1 (en) 2009-03-26
HRP20141102T1 (xx) 2015-03-13
JP2015187106A (ja) 2015-10-29
CN102746240A (zh) 2012-10-24
WO2009039134A1 (en) 2009-03-26
US20140294766A1 (en) 2014-10-02
HK1156033A1 (en) 2012-06-01
CY2015013I2 (el) 2016-04-13
RU2014147354A3 (xx) 2018-07-30
SI2203431T1 (sl) 2011-12-30
JP2013056886A (ja) 2013-03-28
US9139536B2 (en) 2015-09-22
ES2523864T3 (es) 2014-12-02
NO2015011I2 (no) 2015-04-22
CA2699986C (en) 2014-06-17
CA2849420C (en) 2016-07-12
CY1115893T1 (el) 2017-01-25
ES2368879T3 (es) 2011-11-23
DK2368882T3 (en) 2014-12-01
EP2368882A1 (en) 2011-09-28
HK1148273A1 (en) 2011-09-02
CN101842360A (zh) 2010-09-22
EP2203431A1 (en) 2010-07-07
JP5734655B2 (ja) 2015-06-17
NL300729I1 (xx) 2016-01-07
RU2539570C2 (ru) 2015-01-20
CY1115514T1 (el) 2016-04-13
PT2639226T (pt) 2016-12-09
CN104628654A (zh) 2015-05-20
PL2203431T3 (pl) 2012-01-31
US20120244119A1 (en) 2012-09-27
LU92666I2 (fr) 2015-11-24
JP5931683B2 (ja) 2016-06-08
RU2010114827A (ru) 2011-10-27
EP2639226B1 (en) 2016-08-31
NL300729I2 (xx) 2016-01-07
ATE519746T1 (de) 2011-08-15
LTC2203431I2 (lt) 2017-01-25
ES2592961T3 (es) 2016-12-02
CY2015013I1 (el) 2016-04-13
CA2699986A1 (en) 2009-03-26
CN101842360B (zh) 2014-12-17
HUS1500013I1 (hu) 2016-11-28
JP2010539187A (ja) 2010-12-16
PL2368882T3 (pl) 2015-04-30
HRP20110809T1 (hr) 2011-12-31
SI2368882T1 (sl) 2015-02-27
CN102746240B (zh) 2017-10-03
RU2014147354A (ru) 2015-07-10
PT2203431E (pt) 2011-10-12
PT2368882E (pt) 2014-11-27
US8188104B2 (en) 2012-05-29
EP2639226A1 (en) 2013-09-18

Similar Documents

Publication Publication Date Title
NO2015011I1 (no) Dasabuvir eller et salt derav, inkludert dasabuvir natrium monohydrat
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
DK2314594T3 (da) 6-modificerede bicykliske nukleinsyreanaloger
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
CY1114925T1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
WO2008089105A3 (en) Antiviral nucleoside analogs
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
CY1118836T1 (el) Αντι-ιϊκα φωσφονικα αναλογα
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
TW200621313A (en) Pharmaceutical compositions
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
BRPI0507085A (pt) derivados de sulfonamida, composição farmacêutica, usos, processos para preparação e combinação
BRPI0709266B8 (pt) 5-(hidroximetileno e aminometileno) pirimidinas substituídas e composição farmacêutica que as compreende
NO20075111L (no) Farmasoytisk sammensetning
GB0524814D0 (en) Compounds
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
EA201170101A1 (ru) Фармацевтические композиции роувастатина кальция
DE602007010038D1 (de) Pyrimidylderivate als proteinkinaseinhibitoren
WO2007138462A3 (en) Aqueous oral formulations of risperidone
WO2009091346A3 (en) Stable pharmaceutical formulation and preparation methods
DE602004028113D1 (de) Verwendung von 2,3-Dehydronaringenin-Derivaten zur Behandlung von Entzündungsprozessen und diese Derivate enthaltende pharmazeutische Zusammensetzung
ITRM20040099A1 (it) Analoghi nucleosidici ad attivita' antivirale.
HN2005000472A (es) Amidas del acido 5 y 6 -aminoalquil indol -2-carboxilico 3- sustituidas y analogos relacionados como inhibidores de caseina cinasa i.

Legal Events

Date Code Title Description
MK1K Patent expired